-
1Academic Journal
المؤلفون: T. Yu. Demidova, F. O. Ushanova, Т. Ю. Демидова, Ф. О. Ушанова
المصدر: Meditsinskiy sovet = Medical Council; № 6 (2024); 45-52 ; Медицинский Совет; № 6 (2024); 45-52 ; 2658-5790 ; 2079-701X
مصطلحات موضوعية: дислипидемия, hypertriglyceridemia, atherosclerosis, fibrates, fenofibrate, dyslipidemiatype, гипертриглицеридемия, атеросклероз, фибраты, фенофибрат
وصف الملف: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/8269/7292; Дедов ИИ, Шестакова МВ, Викулова ОК, Железнякова АВ, Исаков МА. Эпидемиологические характеристики сахарного диабета в Российской Федерации: клинико-статистический анализ по данным регистра сахарного диабета на 01.01.2021. Сахарный диабет. 2021;24(3):204–221. https://doi.org/10.14341/DM12759.; Ye X, Kong W, Zafar MI, Chen LL. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol. 2019;18(1):48. https://doi.org/10.1186/s12933-019-0851-z.; Жернакова ЮВ, Чазова ИЕ, Ощепкова ЕВ, Шальнова СА, Конради АО, Ротарь ОП и др. Распространенность сахарного диабета в популяции больных артериальной гипертонией. По данным исследования ЭССЕ-РФ. Системные гипертензии. 2018;15(1):56–62. https://doi.org/10.26442/2075-082X_15.1.56-62.; Ощепкова ЕВ, Лазарева НВ, Чазова ИЕ. Оценка качества обследования больных артериальной гипертонией в первичном звене здравоохранения (по данным российского Регистра артериальной гипертонии). Системные гипертензии. 2017;14(2):29–34. Режим доступа: https://journals.eco-vector.com/2075-082X/article/view/29179.; Метельская ВА, Шальнова СА, Деев АД, Перова НВ, Гомыранова НВ, Литинская ОА и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016;19(1):15–23. https://doi.org/10.17116/profmed201619115-23.; Haile K, Timerga A. Dyslipidemia and Its Associated Risk Factors Among Adult Type-2 Diabetic Patients at Jimma University Medical Center, Jimma, Southwest Ethiopia. Diabetes Metab Syndr Obes. 2020;13:4589–4597. https://doi.org/10.2147/DMSO.S283171.; Luo Y, Peng D. Residual Atherosclerotic Cardiovascular Disease Risk: Focus on Non-High-Density Lipoprotein Cholesterol. J Cardiovasc Pharmacol Ther. 2023;28:10742484231189597. https://doi.org/10.1177/10742484231189597.; Su X, Kong Y, Peng D. Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol. Lipids Health Dis. 2019;18(1):134. https://doi.org/10.1186/s12944-019-1080-x.; Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020;41(1):99–109c. https://doi.org/10.1093/eurheartj/ehz785.; Karpov Y, Khomitskaya Y. PROMETHEUS: an observational, cross-sectional, retrospective study of hypertriglyceridemia in Russia. Cardiovasc Diabetol. 2015;14:115. https://doi.org/10.1186/s12933-015-0268-2.; Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Residual Hypertriglyceridemia and Estimated Atherosclerotic Cardiovascular Disease Risk by Statin Use in U.S. Adults With Diabetes: National Health and Nutrition Examination Survey 2007–2014. Diabetes Care. 2019;42(12):2307–2314. https://doi.org/10.2337/dc19-0501.; Kristensen FPB, Christensen DH, Mortensen MB, Maeng M, Kahlert J, Sørensen HT, Thomsen RW. Triglycerides and risk of cardiovascular events in statin-treated patients with newly diagnosed type 2 diabetes: a Danish cohort study. Cardiovasc Diabetol. 2023;22(1):187. https://doi.org/10.1186/s12933-023-01921-5.; Wang Y, Fang Y, Magliano DJ, Charchar FJ, Sobey CG, Drummond GR, Golledge J. Fasting triglycerides are positively associated with cardiovascular mortality risk in people with diabetes. Cardiovasc Res. 2023;119(3):826–834. https://doi.org/10.1093/cvr/cvac124.; Elam M, Lovato L, Ginsberg H. The ACCORD-Lipid study: implications for treatment of dyslipidemia in Type 2 diabetes mellitus. Clin Lipidol. 2011;6(1):9–20. https://doi.org/10.2217/clp.10.84.; Pirillo A, Norata GD, Catapano AL. Production and Metabolism of TriglycerideRich Lipoproteins: Impact of Diabetes. In: Jenkins AJ, Toth PP (eds). Lipoproteins in Diabetes Mellitus. Humana, Cham; 2023, pp. 169–194. https://doi.org/10.1007/978-3-031-26681-2_7.; Ginsberg HN, Packard CJ, Chapman MJ, Borén J, Aguilar-Salinas CA, Averna M et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42(47):4791–4806. https://doi.org/10.1093/eurheartj/ehab551.; Sokooti S, Flores-Guerrero JL, Heerspink HJL, Connelly MA, Bakker SJL, Dullaart RPF. Triglyceride-rich lipoprotein and LDL particle subfractions and their association with incident type 2 diabetes: the PREVEND study. Cardiovasc Diabetol. 2021;20(1):156. https://doi.org/10.1186/s12933-021-01348-w.; Huh JH, Roh E, Lee SJ, Ihm SH, Han KD, Kang JG. Remnant Cholesterol Is an Independent Predictor of Type 2 Diabetes: A Nationwide Population-Based Cohort Study. Diabetes Care. 2023;46(2):305–312. https://doi.org/10.2337/dc22-1550.; Bharti RK, Koshewara P, Negi PS, Kaundal PK. Is fixed dose combination of rosuvastatin with fenofibrate more effective than high dose Rosuvastatin inpatients with stable coronary artery disease with mixed dyslipidemia? A study. Panacea J Med Sci. 2023;13(2):504–512. https://10.18231/j.pjms.2023.095; Keech AC, Mitchell P, Summanen PA, O’Day J, Davis TM, Moffitt MS et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet. 2007;370(9600):1687–1697. https://doi.org/10.1016/S0140-6736(07)61607-9.; ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–1574. https://doi.org/10.1056/NEJMoa1001282.; Kim NH, Choi J, Kim YH, Lee H, Kim SG. Addition of fenofibrate to statins is associated with risk reduction of diabetic retinopathy progression in patients with type 2 diabetes and metabolic syndrome: A propensitymatched cohort study. Diabetes Metab. 2023;49(3):101428. https://doi.org/10.1016/j.diabet.2023.101428.; Jo SH, Nam H, Lee J, Park S, Lee J, Kyoung DS. Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort. Diabetes Care. 2021;44(8):1868–1876. https://doi.org/10.2337/dc20-1533.; Демидова ТЮ, Плахотняя ВМ. Предиабет: фактор риска сердечно-сосудистых заболеваний и «окно возможностей» для их профилактики. FOCUS Эндокринология. 2023;4(2):6–11. https://doi.org/10.15829/1560-4071-2023-24.; Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm – 2023 Update. Endocr Pract. 2023;29(5):305–340. https://doi.org/10.1016/j.eprac.2023.02.001.; Ежов МВ, Кухарчук ВВ, Сергиенко ИВ, Алиева АС, Анциферов МБ, Аншелес АА и др. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. https://doi.org/10.15829/1560-4071-2023-5471.; Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875–1884. https://doi.org/10.1016/S0140-6736(10)60656-3.; Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM et al. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. N Engl J Med. 2022;387(21):1923–1934. https://doi.org/10.1056/ NEJMoa2210645.; Бойцов СА, Погосова НВ, Аншелес АА, Бадтиева ВА, Балахонова ТВ, Барбараш ОЛ и др. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. https://doi.org/10.15829/1560-4071-2023-5452.; https://www.med-sovet.pro/jour/article/view/8269